BG104059A - Diabetes treatment with rosiglytazone and insulin - Google Patents

Diabetes treatment with rosiglytazone and insulin

Info

Publication number
BG104059A
BG104059A BG104059A BG10405900A BG104059A BG 104059 A BG104059 A BG 104059A BG 104059 A BG104059 A BG 104059A BG 10405900 A BG10405900 A BG 10405900A BG 104059 A BG104059 A BG 104059A
Authority
BG
Bulgaria
Prior art keywords
rosiglytazone
insulin
diabetes treatment
treatment
nontoxic
Prior art date
Application number
BG104059A
Other languages
Bulgarian (bg)
Inventor
Stephen Smith
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG104059A publication Critical patent/BG104059A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

The invention relates to a method for the treatment of diabetes mellitus and conditions related to it in mammals. The method consists in the administration of effective, nontoxic and pharmaceutically acceptable quantity of rosiglytazone and insulin. 15 claims
BG104059A 1997-06-18 2000-01-06 Diabetes treatment with rosiglytazone and insulin BG104059A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Publications (1)

Publication Number Publication Date
BG104059A true BG104059A (en) 2000-10-31

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104059A BG104059A (en) 1997-06-18 2000-01-06 Diabetes treatment with rosiglytazone and insulin

Country Status (30)

Country Link
EP (1) EP0999837A1 (en)
JP (1) JP2002504138A (en)
KR (1) KR20010013843A (en)
CN (1) CN1133431C (en)
AP (1) AP1287A (en)
AR (2) AR012997A1 (en)
AU (1) AU8216398A (en)
BG (1) BG104059A (en)
BR (1) BR9810444A (en)
CA (1) CA2294141A1 (en)
CO (1) CO4940454A1 (en)
DZ (1) DZ2521A1 (en)
EA (1) EA004800B1 (en)
GB (1) GB9712866D0 (en)
HU (1) HUP0003260A3 (en)
ID (1) ID23951A (en)
IL (1) IL133143A0 (en)
IN (1) IN189723B (en)
MA (1) MA26511A1 (en)
NO (1) NO996265L (en)
OA (1) OA11517A (en)
PE (1) PE104499A1 (en)
PL (1) PL343123A1 (en)
SK (1) SK179399A3 (en)
TR (1) TR199903095T2 (en)
TW (1) TW587937B (en)
UA (1) UA70299C2 (en)
UY (1) UY25050A1 (en)
WO (1) WO1998057636A1 (en)
ZA (1) ZA985237B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AR023568A1 (en) 1999-04-23 2002-09-04 Smithkline Beecham Plc A PROCEDURE FOR PREPARING A POLYMORPHIC FORM OF MALEIC ACID SALT DERIVED FROM TIAZOLIDINA-2,4-DIONA
USRE40876E1 (en) * 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
WO2004041275A1 (en) 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (en) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 Solid oral preparation containing rosiglitazone and cetirizine hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ274346A (en) * 1993-09-15 1997-06-24 Sankyo Co Use of various thiazolidine-2,4-dione and oxazolidine-2,4-dione derivatives to prevent or delay onset of non-insulin dependent diabetes mellitus
KR19990036290A (en) * 1995-08-10 1999-05-25 로즈 암스트롱 Reduction of Exogenous Insulin Dosage in Non-insulin-Dependent Diabetic Patients
BR9610624A (en) * 1995-09-18 1999-03-16 Ligand Pharm Inc Treatment of dmndi with rxr agonists

Also Published As

Publication number Publication date
AP9901718A0 (en) 1999-12-31
CA2294141A1 (en) 1998-12-23
CN1260715A (en) 2000-07-19
EP0999837A1 (en) 2000-05-17
JP2002504138A (en) 2002-02-05
EA004800B1 (en) 2004-08-26
TW587937B (en) 2004-05-21
ID23951A (en) 2000-06-08
DZ2521A1 (en) 2003-02-08
TR199903095T2 (en) 2000-08-21
BR9810444A (en) 2000-09-05
UA70299C2 (en) 2004-10-15
NO996265D0 (en) 1999-12-17
EA200000042A1 (en) 2000-08-28
AR015894A1 (en) 2001-05-30
GB9712866D0 (en) 1997-08-20
AU8216398A (en) 1999-01-04
IN189723B (en) 2003-04-19
CO4940454A1 (en) 2000-07-24
IL133143A0 (en) 2001-03-19
OA11517A (en) 2004-02-04
PE104499A1 (en) 2000-01-13
SK179399A3 (en) 2000-11-07
HUP0003260A3 (en) 2001-12-28
NO996265L (en) 1999-12-17
HUP0003260A2 (en) 2001-05-28
AP1287A (en) 2004-06-26
ZA985237B (en) 2000-02-17
UY25050A1 (en) 2000-09-29
MA26511A1 (en) 2004-12-20
KR20010013843A (en) 2001-02-26
WO1998057636A1 (en) 1998-12-23
AR012997A1 (en) 2000-11-22
CN1133431C (en) 2004-01-07
PL343123A1 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
BG104060A (en) Diabetes treatment with thiazolyidindion and methformine
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
AU2373400A (en) Shelf-stable formulation of glucagon-like peptide-1
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
AU5456598A (en) Insulin delivery enhanced by coached breathing
WO2000057900A3 (en) Factor for regulation of neurite growth
EP0647133A4 (en) Compositions and methods for enhanced drug delivery.
AU2272097A (en) Drug delivery compositions suitable for intravenous injection
HK1070589A1 (en) Prolanged delivery of peptides
EP0767687A4 (en) Inplantable drug delivery pump
MY129220A (en) "use of glp-1 analogs and derivatives administered peripherally in regulation of obesity"
EP0658111A4 (en) Methods for enhancing drug delivery with modified saponins.
IL199364A0 (en) Use of pyy for preparation of a medicament for modification of feeding behavior
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
CA2284482A1 (en) Treatment of cardiomyopathy
BG104135A (en) Diabetes treatment with thiazolydindion, a form increasing the insulin and biguanide secretion
ZA953537B (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
UA42819C2 (en) Enrofloxacine injection or infusion solutions
EP0683668A4 (en) Compositions and methods for transdermal drug delivery.
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
AU8019898A (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome
WO1999053064A3 (en) Methods of delivering glp-1
IL143088A0 (en) A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method